A Phase 3 interventional study of Budesonide/formoterol (SYMBICORT) pMDI and Formoterol Turbuhaler in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 140 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-09-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 14th largest by enrollment, is one of 5 that started in 2007, is one of 40 in phase 3, and was the 16th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,200 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 27th largest by enrollment of the 194 interventional ones that give a count, is one of 9 that started in 2007, is one of 76 in phase 3, and was the 18th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year
Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.
Time frame: 12 months
Rate of Exacerbations Per Subject-year
Rate of exacerbations per subject-year
Time frame: 12 months
Pre-dose Forced Expiratory Volume in 1 Second (FEV1)
Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.
Time frame: 12 months
Morning Peak Expiratory Flow (PEF)
Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.
Time frame: 12 months
Evening PEF
Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.
Time frame: 12 months
Dyspnea Symptom Scores
Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.
Time frame: 12 months
Use of Rescue Medication
Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.
Time frame: 12 months
St. George's Respiratory Questionnaire (SGRQ) Score
Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.
Time frame: 12 months
First patient randomized on 02 January 2007. The last patient completed study on 27 August 2009. The study randomized patients in the United States and Mexico (93 investigational sites), South America (48 investigational sites), and South Africa (20 investigational sites).
| Milestone | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Started | 407 | 408 | 404 |
| Completed | 290 | 290 | 271 |
| Not completed | 117 | 118 | 133 |
| Withdrew: Adverse event | 39 | 40 | 50 |
| Withdrew: Withdrawal by subject | 45 | 49 | 52 |
| Withdrew: Lost to follow-up | 8 | 10 | 6 |
| Withdrew: Protocol violation | 4 | 7 | 8 |
| Withdrew: Randomized in error | 9 | 6 | 7 |
| Withdrew: Moving out of state | 2 | 0 | 1 |
| Withdrew: Physician decision | 10 | 5 | 6 |
| Withdrew: Spirometry mouthpiece issues | 0 | 1 | 2 |
| Withdrew: Incorrect medication kit dispensed | 0 | 0 | 1 |
Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.
| Exacerbations | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year | 0.75 | 0.84 | 1.14 |
Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.
| Liters (L) | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Pre-dose Forced Expiratory Volume in 1 Second (FEV1) | 0.07 ± 0.18 | 0.07 ± 0.17 | 0.04 ± 0.17 |
Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.
| L/min | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Morning Peak Expiratory Flow (PEF) | 19.82 ± 37.96 | 19.61 ± 38.83 | 15.81 ± 41.43 |
Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.
| L/min | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Evening PEF | 17.62 ± 37.86 | 17.77 ± 37.67 | 14.08 ± 41.13 |
Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.
| Scores on a scale | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Dyspnea Symptom Scores | -0.30 ± 0.65 | -0.29 ± 0.70 | -0.24 ± 0.67 |
Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.
| Number of inhalations | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Use of Rescue Medication | -1.21 ± 3.57 | -1.03 ± 3.74 | -0.28 ± 3.60 |
Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.
| Scores on a scale | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| St. George's Respiratory Questionnaire (SGRQ) Score | -6.23 ± 14.72 | -5.00 ± 16.10 | -5.71 ± 15.31 |
Rate of exacerbations per subject-year
| Rate | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Rate of Exacerbations Per Subject-year | 0.639 | 0.745 | 1.029 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SYM 160/4.5 X 2 BID | — | 79/407 (19.4%) | 193/407 (47.4%) |
| SYM 80/4.5 X 2 BID | — | 61/408 (15%) | 177/408 (43.4%) |
| FOR 4.5 X 2 BID | — | 73/403 (18.1%) | 176/403 (43.7%) |
| Event | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 32/407 | 33/408 | 34/403 |
| Pneumonia BacterialInfections and infestations | 13/407 | 4/408 | 7/403 |
| Atrial FibrillationCardiac disorders | 6/407 | 3/408 | 0/403 |
| Myocardial InfarctionCardiac disorders | 0/407 | 1/408 | 3/403 |
| BronchitisInfections and infestations | 0/407 | 0/408 | 3/403 |
| Cardiac Failure CongestiveCardiac disorders | 3/407 | 1/408 | 0/403 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 3/407 | 2/408 | 1/403 |
| Cardiac ArrestCardiac disorders | 0/407 | 1/408 | 2/403 |
| Cor PulmonaleCardiac disorders | 0/407 | 1/408 | 2/403 |
| GastritisGastrointestinal disorders | 0/407 | 0/408 | 2/403 |
| Event | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID |
|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 57/407 | 46/408 | 68/403 |
| HeadacheNervous system disorders | 56/407 | 46/408 | 43/403 |
| NasopharyngitisInfections and infestations | 31/407 | 35/408 | 41/403 |
| BronchitisInfections and infestations | 37/407 | 32/408 | 25/403 |
| InfluenzaInfections and infestations | 29/407 | 26/408 | 25/403 |
| Upper Respiratory Tract Infection BacterialInfections and infestations | 18/407 | 23/408 | 17/403 |
| Back PainMusculoskeletal and connective tissue disorders | 21/407 | 18/408 | 21/403 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 21/407 | 13/408 | 14/403 |
| HypertensionVascular disorders | 21/407 | 16/408 | 9/403 |
| Age Continuous(Years) | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID | Total |
|---|---|---|---|---|
| Mean | 63.8 ± 9.4 | 62.8 ± 9.22 | 62.5 ± 9.36 | 63.0 ± 9.34 |
| Sex: Female, Male(Participants) | SYM 160/4.5 X 2 BID | SYM 80/4.5 X 2 BID | FOR 4.5 X 2 BID | Total |
|---|---|---|---|---|
| Female | 145 | 144 | 174 | 463 |
| Male | 262 | 264 | 229 | 755 |
Showing the first 100 of 140 sites across 9 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →